YOM KIPPUR SALE15% OFF everything until 29 SeptemberEnds in —Shop the Sale →
Free Shipping on orders over $250 AUDDispatched from Melbourne, Australia — 3–7 business daysPlain, discreet packaging on every orderSecure Checkout, PayID & Card available
Research 9 min read8 January 2026

BPC-157 Research Overview: What the Science Shows

A comprehensive review of preclinical BPC-157 research including its studied mechanisms, molecular structure, and key findings from published literature.

Written by the Peptide Labs Research Team

What is BPC-157?

BPC-157 — specification

Also sold as: Body Protection Compound-157
Class
Synthetic pentadecapeptide
Molecular target
No single characterised receptor
Sequence / structure
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular formula
C₆₂H₉₈N₁₆O₂₂
Molecular weight
1419.53 Da
CAS number
137525-51-0
Published human evidence
No published human trials
Studied in
Tissue repair research · Gut research · Angiogenesis research

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is a partial sequence derived from the gastric protein BPC (body protection compound). Unlike many research peptides, BPC-157 does not occur naturally in isolation; it is a synthesised research compound.

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

CAS: 137525-51-0

Molecular Weight: 1419.53 Da

Structure-Activity Considerations

BPC-157's 15-residue sequence is notably rich in proline and glycine, two residues known more broadly in peptide chemistry for their influence on backbone flexibility — proline restricts rotation and introduces kinks, while glycine's lack of a side chain allows tight turns. This composition is part of why the compound is a frequent subject of structure-activity research: investigators studying which residues are necessary for its observed *in vitro* and *in vivo* effects have used truncated and substituted analogues to map activity back to specific segments of the sequence, rather than treating the full 15-mer as a single indivisible unit.

Key Research Areas

Angiogenesis Research

Multiple preclinical studies have investigated BPC-157's effects on angiogenesis (new blood vessel formation). Research suggests upregulation of VEGFR2 and FAK-paxillin signalling pathways, with in vitro models showing effects on endothelial cell migration consistent with a pro-angiogenic signalling profile.

Gastrointestinal Research

BPC-157 has been extensively studied in rodent models for gastrointestinal protective effects, including research on ulcer models, intestinal anastomosis healing, and inflammatory bowel models. Much of the compound's early research history originates from this area, given BPC-157's derivation from a gastric protective protein sequence.

Tendon and Bone Research

Several rodent studies have examined BPC-157 in tendon-to-bone healing models, with findings related to collagen synthesis and fibroblast activity. Some of this literature specifically examines outer segments of tendons at the enthesis (the tendon-bone junction), an area of particular research interest because of its comparatively poor natural healing capacity.

Neurological Research

Preclinical studies have investigated BPC-157 in CNS models, including dopaminergic and serotonergic pathway interactions, with some research groups examining its effects in models of neurological injury alongside its more established gastrointestinal and musculoskeletal research lines.

Research Literature Summary

Published research on BPC-157 spans over 20 years, with most studies conducted in rodent models. Key research groups at the University of Zagreb (Croatia) have published extensively on the compound, with the bulk of the foundational literature concentrated in gastroenterology and pharmacology journals rather than clinical medicine — a pattern consistent with a compound still firmly in the preclinical research stage.

Notable research includes:

  • •Sikiric et al. (multiple publications 1990s–2020s): Gastrointestinal and systemic effects
  • •Studies in *Journal of Physiology and Pharmacology*, *European Journal of Pharmacology*

Researchers evaluating this literature should note that a large proportion of published studies originate from a relatively concentrated set of research groups, which is worth factoring into any independent assessment of the evidence base — a common consideration when reviewing any compound's preclinical literature.

Important Research Limitations

  • •The majority of BPC-157 research is preclinical (in-vitro and animal models)
  • •Human clinical trial data is limited
  • •Mechanism of action remains incompletely characterised
  • •Much of the published literature originates from a concentrated set of research groups, which is a relevant consideration when weighing the independence of the evidence base
  • •All research use should adhere to applicable ethical and regulatory standards

Purchasing Research-Grade BPC-157

Our BPC-157 10mg is independently verified at 99.2% HPLC purity with full COA documentation including mass spectrometry identity confirmation.

Disclaimer: All information is based on published preclinical research literature and is for educational purposes only. Not medical advice. All research must be conducted in accordance with applicable laws and regulations.

Shop Research-Grade Peptides

99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne

Shop All Peptides